Literature DB >> 15049305

Reviving Ulysses contracts.

Ryan Spellecy1.   

Abstract

Ulysses contracts have faced paternalism objections since they first were proposed. Since the contracts are designed to override a present request from a legally competent patient in favor of a past request made by that patient, enforcement of these contracts was argued to be unjustifiable strong paternalism. Recent legal developments and new theories of practical reasoning suggest that the discussion of Ulysses contracts should be revived. This paper argues that with a proper understanding of the future-directed planning embodied in Ulysses contracts, the charge of strong paternalism can be answered, and the enforcement of some Ulysses contracts may be justified under the rubric of weak paternalism.

Entities:  

Keywords:  Analytical Approach; Legal Approach; Mental Health Therapies; Professional Patient Relationship

Mesh:

Year:  2003        PMID: 15049305     DOI: 10.1353/ken.2004.0010

Source DB:  PubMed          Journal:  Kennedy Inst Ethics J        ISSN: 1054-6863


  5 in total

1.  Ulysses arrangements in psychiatric treatment: towards proposals for their use based on 'sharing' legal capacity.

Authors:  Phil Bielby
Journal:  Health Care Anal       Date:  2014-06

2.  Coercion and pressure in psychiatry: lessons from Ulysses.

Authors:  Guy Widdershoven; Ron Berghmans
Journal:  J Med Ethics       Date:  2007-10       Impact factor: 2.903

3.  Thwarting the Diseased Will: Ulysses Contracts, the Self and Addiction.

Authors:  Kirsten Bell
Journal:  Cult Med Psychiatry       Date:  2015-09

4.  The limits of traditional approaches to informed consent for genomic medicine.

Authors:  Thomas May; Kaija L Zusevics; Arthur Derse; Kimberly A Strong; Jessica Jeruzal; Alison La Pean Kirschner; Michael H Farrell; Ryan Spellecy
Journal:  HEC Forum       Date:  2014-09

5.  Power and control: contracts and the patient-physician relationship.

Authors:  S R Lieber; S Y Kim; M L Volk
Journal:  Int J Clin Pract       Date:  2011-12       Impact factor: 2.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.